Quinolones and ALF risk

Quinolones, a popular and powerful anti-biotic with broad coverage and reasonable safety, was concerned to be associated with acute liver failure (ALF). A study published in the Journal of Gastroenterology and Hepatology on 14 March 2021 by, among others, RSI’s Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski, investigated the risk of ALF within 30 days after receiving a systemically administered dose of the quinolone antibiotic, in individuals with no history of liver diseases.

Although the primary analysis did not reveal an overall association between quinolones as a class and ALF risk, a possible risk was identified among those with no or few comorbidities, those ≤ 60 years of age, women, men, African Americans, and Caucasians.

The authors noted that elevated risks seen in some subgroups warrant further investigation.

The paper is available by clicking here.

Posted in

More RSI News

Quinolones and ALF risk

June 30, 2021
Risk Sciences International 1

Quinolones, a popular and powerful anti-biotic with broad coverage and reasonable safety, was concerned to be associated with acute liver failure (ALF). A study published…

Read News Item

US FDA FAERS and quinolones

June 22, 2021
RSI logo in white

Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised…

Read News Item

Advancing Toxicity Testing webinar

May 25, 2021
Daniel Krewski at the CAAT Webinar

The Center for Alternatives to Animal Testing and the Animal-Free Safety Assessment recently held their annual meeting on advancing toxicity testing in the 21st century…

Read News Item

USC appoints Dr. Mattison distinguished professor

March 16, 2021
USC Arnold School of Public Health

Dr. Donald Mattison, RSI’s Senior Vice-President and Chief Medical Officer, has accepted an appointment as a University of South Carolina Health Sciences Distinguished Professor in the in…

Read News Item